Incb-053914
Uzansertib (INCB053914) is a novel, ATP-competitive, small molecule, pan-inhibitor of PIM kinases with IC50 values of 0.24 nM, 30 nM and 0.12 nM for PIM1, PIM2 and PIM3 respectively in biochemical assays. CAS No. 2088852-47-3 Selleck's Uzansertib (INCB053914) has been cited by 2 Publications Cancer Lett,2024476:23-33 WebDetroit is a city located in Wayne County Michigan.It is also the county seat of Wayne County.With a 2024 population of 621,193, it is the largest city in Michigan and the 27th …
Incb-053914
Did you know?
WebFrom our 104,000-sq. ft. state-of-the-art facility in Detroit, Michigan, our multiple automatic and semi-automatic processing lines finish parts for industries ranging from automotive, … WebOct 30, 2024 · Based on the up-regulation of the proviral integration site of the Moloney murine leukemia virus (Pim) kinase family (Pim1, 2, and 3) observed in several types of leukemias and lymphomas, the development of pan-Pim inhibitors is an attractive therapeutic strategy. While only PIM447 and AZD1208 have entered the clinical stages. To …
WebDetroit, Michigan's Local 4 News, headlines, weather, and sports on ClickOnDetroit.com. The latest local Detroit news online from NBC TV's local affiliate in Detroit, Michigan, WDIV - …
WebINCB053914 INCB-053914 1620012-39-6 INCB053914 (INCB-053914) is a novel potent, and selective ATP-competitive, pan-PIM kinase inhibitor with IC50 of 0.24/30.0/0.12 nM for PIM1/2/3, respectively supplier price datasheet … WebINCB053914; PIM inhibitor
WebAug 1, 2015 · INCB53914 is a pan-PIMkinase inhibitor, and the only current PIM-kinase inhibitor entering evaluation in human trials as a potential treatment in myeloid disease. 119 Pevonedistat (MLN4924) is a...
WebUzansertib (INCB053914) phosphate is an orally active, ATP-competitive pan- PIM kinase inhibitor with IC50 s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. … bra sizing m\u0026sWebINCB053914 is a novel, ATP-competitive, small molecule, pan-inhibitor of PIM kinases. INCB053914 is potent against PIM1, PIM2 and PIM3 and highly selective. INCB053914 is active as a single agent in the majority of cell lines derived from different hematological malignancies, including MM, AML, DLBCL, MCL and T-ALL, with IC50 values ranging from … brady\u0027s pubWebFind technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes links to find associated … bra yoga topsWebOct 8, 2015 · Prot #INCB 53914-101: A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies. Kaplan, Jason B (PD/PI) Medicine, Hematology Oncology Division; Project: Research project. Overview; Project Details Status: Finished: Effective start/end date: 10/8/15 → 10/8/18: Funding. brad takeiWebDescription: INCB053914, also known as Uzansertib, is a novel, potent, and selective adenosine triphosphate-competitive pan-PIM kinase inhibitor. In vitro, INCB053914 … bradypnoea ukWebINCB053914 phosphate is an inhibitor of Pim extracted from patent WO 2024044730 A1, compound 1; has an IC50 of less than 35 nM. Availability: In stock Free Overnight Delivery … bradstone europa block pavingWebINCB053914 (INCB-053914) is a novel potent, and selective ATP-competitive, pan-PIM kinase inhibitor with IC50 of 0.24/30.0/0.12 nM for PIM1/2/3, respectively; INCB053914 is highly selective against a panel of more than 50 kinases (>475-fold selectivity) with exception of RSK2 (IC50=7.1 uM); inhibits cellular proliferation in a panel of cell lines … brady\u0027s run ice rink